



# Pharmacy and Therapeutics Committee

July 10, 2017 12:00pm -5:00 pm  
Gold Room, 3<sup>rd</sup> Floor  
701 E. Jefferson Phoenix, AZ 85034

## AGENDA

Teleconference: 1-877-820-7831 Passcode: 960711

### Agenda Topics

Noon

**Welcome and Introductions:** Sara Salek, MD, Chief Medical Officer, AHCCCS

- April 13, 2017 P&T Minutes Review and Vote
- Call for P&T Members for 2018 to 2020

### AHCCCS and Behavioral Health Drug Lists

12:15

**Supplemental Rebate Class Review:**

1. Oral Atypical (Second Generation) Antipsychotics
  - a. Clinical review: Rick Pope: Provider Synergies
  - b. Pharma Testimony:
    - i. Rexulti: Kristin Pareja, Otsuka
  - c. Public Testimony:
    - i. Kurt von Behrmann, N.A.M.I. Family Support
2. Long-Acting Injectable Antipsychotics
  - a. Clinical review: Rick Pope: Provider Synergies
  - b. Pharma Testimony:
    - i. Abilify Maintena: Kristin Pareja, Otsuka
    - ii. Aristada: Kenneth Berry, Alkermes
    - iii. Invega Sustenna: Steve Zona, Janssen Scientific Affairs
    - iv. Trinza: Steve Zona, Janssen Scientific Affairs
  - c. Public Testimony:
    - i. Mathew Avila, Community Health Associates
    - ii. Carol Olson MD, Maricopa Integrated Health System
    - iii. Thomas Gazda, MD
    - iv. Charles Goldstein, MD
    - v. Kristina Sabetta, Mental Health America of Arizona
3. Stimulants & Related Agents
  - a. Clinical review: Rick Pope: Provider Synergies
  - b. Pharma Testimony:
    - i. Adzenys XR-ODT: George Kehner, Neos Therapeutics
    - ii. Aptensio XR: Christina Heiner, Rhodes Pharmaceuticals
    - iii. Dyanavel XR: Zulma Schlossberg, Tris Pharma
    - iv. Quillivant XR: Steve Fuchs, Pfizer
    - v. Quillichew: Steve Fuchs, Pfizer
  - c. Public Testimony: None
4. Pancreatic Enzymes
  - a. Clinical review: Rick Pope: Provider Synergies
  - b. Pharma Testimony:
  - c. Public Testimony: None
5. Anticoagulants
  - a. Clinical review: Rick Pope: Provider Synergies

2:00	<p>b. Pharma Testimony:</p> <ol style="list-style-type: none"> <li>i. Eliquis: Jon Glover, Pfizer</li> <li>ii. Xarelto: Steve Zona, Janssen Scientific Affairs</li> </ol> <p>c. Public Testimony: None</p> <p><b>Non-Supplemental Rebate Class Review:</b></p> <ol style="list-style-type: none"> <li>1. Hemophilia Factor <ol style="list-style-type: none"> <li>a. Clinical review: Rick Pope: Provider Synergies</li> <li>b. Pharma Testimony: <ol style="list-style-type: none"> <li>i. Alprolix: Alex Bitting, Bioverativ</li> <li>ii. Eloctate: Alex Bitting, Bioverativ</li> <li>iii. Kogenate FS: Trina Ballard, Bayer</li> <li>iv. Kovaltry rFVIII: Trina Ballard, Bayer</li> </ol> </li> <li>C. Public Testimony: <ol style="list-style-type: none"> <li>i. Danielle Nance, Arizona Bleeding Disorders Health and Wellness Center</li> <li>ii. Andrew Blacklidge, Arizona Hemophilia Association</li> <li>iii. Esteban Gomez, Phoenix Children’s Hospital Hemophilia Center</li> <li>iv. Josue Terazon</li> <li>v. Tyler Lipinski</li> <li>vi. David Cabrera</li> <li>vii. Tony Hernandez</li> <li>viii. Marco Bojorges</li> <li>ix. Brent Davila</li> </ol> </li> </ol> </li> </ol> <p><b>Executive Session</b></p> <p><b>Supplemental Rebate Class Discussions:</b></p> <ul style="list-style-type: none"> <li>• Hypoglycemics, Insulin &amp; Related Agents – postponed until the July meeting to review additional data.</li> <li>• Oral Atypical (Second Generation) Antipsychotics</li> <li>• Long-Acting Injectable Antipsychotics</li> <li>• Stimulants &amp; Related Agents</li> <li>• Pancreatic Enzymes</li> <li>• Anticoagulants</li> </ul> <p><b>Non-Supplemental Rebate Class Discussion:</b></p> <ul style="list-style-type: none"> <li>• Hemophilia Factor</li> </ul>
3:15	<p>Break</p> <p><b>Public Therapeutic Class Votes</b></p>
4:00	<p>AHCCCS Drug Lists Alignment for Behavioral Health Drugs &amp; Vote – Michelle Cavner, Pharmacy Director, MMIC</p>
4:20	<p>Biosimilar Update:</p> <ul style="list-style-type: none"> <li>• Inflectra (infliximab-dyyb)</li> <li>• b. Renflexis (Infliximab-abda)</li> </ul>
4:25	<p>New Drug Reviews: Non-Supplemental Rebate Class: <i>Suzi Berman, AHCCCS</i></p> <ul style="list-style-type: none"> <li>• Austedo (Deutertrabenazine)</li> <li>• Dupixent (Dupiluma)</li> <li>• Rhofade (Oxymetazoline HCL 1% Cream)</li> <li>• Symproic ( Naldemedine)</li> <li>• Xadago (Safinamide)</li> <li>• Ingrezza (Valbenazine)</li> <li>• Emflaza (Deflazacort)</li> </ul>

5:00

**Meeting Adjourned**

**2017 Meeting Dates:** Thursday, October 12, 2017